<DOC>
	<DOCNO>NCT01799590</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy topiramate participant migraine ( type severe headache occur periodically often associate nausea , vomit constipation diarrhea ) complete JNS019-JPN-02 study .</brief_summary>
	<brief_title>Continuous Treatment Study Topiramate Migraine Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter ( conduct one center ) , dose-titration ( dose escalation/reduction ) study topiramate participant migraine . This study continuous study participant enrol JNS019-JPN-02 study . Participants complete JNS019-JPN-02 study receive treatment 52 week start Visit 4 JNS019-JPN-02 study . The present study consist 3 week Transfer period ( period dose titration take place along dose titration new treatment initiate 25 milligram per day [ 25mg/day ] ) , Continuous treatment period ( 32 week ) , Exit period ( 3 week ) Follow-up period ( 4 week ) . Participants Continuous treatment period receive topiramate tablet orally dose range 50 mg/day 100 mg/day . Dose increase decrease per Investigator 's discretion . The maximum daily dose 200 mg/day . Efficacy primarily evaluate change Baseline number monthly migraine attack Continuous treatment period . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Participants complete JNS019JPN02 study discontinue study Week 4 fixeddose period insufficient efficacy Participants discontinue JNS019JPN02 study adverse event unrelated underlying disease Participants judge unfavorable transfer study safety assessment JNS019JPN02 study Pregnant ( carry unborn baby ) female participant Other participant consider ineligible per Investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Topiramate</keyword>
</DOC>